Cumberland FIGHT DMD trial shows 30% MYL3 cut
Cumberland Pharmaceuticals Inc. presented 36-month data from its Phase 2 FIGHT DMD trial, showing ifetroban significantly reduced heart damage biomarkers MYL3 and MYOD1 by 30% and 50%, respectively, while increasing cardioprotective proteins FGF16 and TSPAN7. The therapy maintained a favorable safety profile with no treatment-related serious adverse events, reinforcing its potential to treat DMD-associated cardiomyopathy.
*this image is generated using AI for illustrative purposes only.
Cumberland Pharmaceuticals Inc. presented updated 36-month results from its Phase 2 FIGHT DMD trial at the Parent Project Muscular Dystrophy (PPMD) annual conference in Orlando, Florida, on June 26, 2026. The new analyses demonstrate the cardioprotective effect of ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, showing significant reductions in key biomarkers of heart muscle damage. The findings reinforce the therapy's potential to address cardiomyopathy, the leading cause of death in patients with DMD.
The 12-month Phase 2 trial previously demonstrated that high-dose ifetroban treatment resulted in a significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. The study also included reductions in cardiac damage markers NT-proBNP and cardiac troponin I in the high-dose group. All patients who completed the 12-month study opted to continue in the open-label extension.
New findings from 36 months of treatment across the Phase 2 trial and the open-label extension further characterize ifetroban's cardioprotective effect. The drug maintained a favorable safety profile with no treatment-related serious adverse events or new safety concerns. Evaluation of novel blood biomarkers identified significant changes compared to placebo:
| Biomarker | Change | Function |
|---|---|---|
| MYL3 | 30% reduction | Marker of heart muscle damage |
| MYOD1 | 50% reduction | Marker of cell damage |
| FGF16 | 2.4-fold increase | Cardioprotective protein |
| TSPAN7 | 2.1-fold increase | Tissue repair protein |
"The improvement in cardiac function we observed in the 12-month study is supported by additional biological evidence that ifetroban can help protect the heart from ongoing injury," said A.J. Kazimi, Cumberland CEO.
Ifetroban is a once-daily oral medication that blocks the thromboxane receptor, playing a key role in inflammation and fibrosis. The drug has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the U.S. Food and Drug Administration (FDA) for DMD-associated cardiomyopathy. There are currently no approved treatments specifically targeting DMD heart disease.
Cumberland has secured a growing portfolio of patents protecting the product for this indication. Next steps include the completion of long-term treatment analyses and the conduct of additional supportive studies.
What is the anticipated timeline for initiating a Phase 3 pivotal trial following the completion of long-term treatment analyses?
How will Cumberland leverage the Fast Track Designation to accelerate the regulatory approval pathway for ifetroban?
What specific endpoints will be prioritized in the upcoming supportive studies to further demonstrate clinical efficacy?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
